BXTAccelyon and Hitachi Medical Systems to support #TRexit
As the national campaign to eradicate traditional transrectal (TRUS) biopsies from the prostate cancer pathway gains momentum, BXTAccelyon is pleased to announce a training and promotion partnership with Hitachi Medical Systems UK.
Approaching 100 centres across England are now using the PrecisionPoint biopsy device, which allows transperineal (TP) biopsies to be conducted under local anaesthetic, helping to decrease infection rates and allowing for convenient, freehand access within an outpatient environment.
DATE: BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the revolutionary freehand transperineal prostate biopsy access system, has signed a global agreement with MRI PRO. The partnership will see BXTAccelyon distribute this new, online self-learning tool for prostate MRI diagnostics, designed and developed by a team of specialist MRI radiologists and urologists.
With high-level evidence now confirming prostate MRI’s place in the diagnostic process of prostate cancer detection, as well as adopt...
“TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now
A new ‘Open Access’ perspective paper by Grummet, J., Gorin, M.A., Popert, R. et al. as published in Springer Nature’s Prostate Cancer and Prostatic Diseases, is calling for the full, global eradication of the transrectal (TRUS) prostate biopsy to transperineal (TP) biopsy under local anaesthetic to be instigated in 2020.
The authors assert that “a well-planned global ‘TRexit’ with a phase-out period of TR biopsy led by centres experienced in TP biopsy, should be […] aiming for completion by the end of 2022.”